Dr. Philip J. Ferrone, MD
Ophthalmology (Ophthalmology Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,225
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: Harvard Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
NY license 208646
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- North Shore University Hospital Manhasset, NY
Medical groups
- Long Island Vitreo Retinal Consultants PC (20 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,225
- Services billed
- 39,766
- Patients’ average age
- 79
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 23,760 | 67 |
| Imaging of retina | 2,779 | 1,031 |
| Injection, aflibercept, 1 mg | 1,668 | 210 |
| Injection of drug into eye | 1,521 | 386 |
| Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 1,233 | 88 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,094 | 695 |
| Injection, pegcetacoplan, intravitreal, 1 mg | 795 | 39 |
| Extended exam of the back part of the eye with retinal drawing | 759 | 532 |
| Established patient problem focused exam of visual system | 623 | 350 |
| Extended exam of the back part of the eye with optic nerve drawing | 569 | 385 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Great Neck, NY | 133 |
| Latanoprost Other prescribers in Great Neck, NY | 71 |
| Ofloxacin Other prescribers in Great Neck, NY | 58 |
| Dorzolamide-Timolol (dorzolamide hcl/timolol maleat) Other prescribers in Great Neck, NY | 49 |
| Travoprost Other prescribers in Great Neck, NY | 33 |
| Ketorolac Tromethamine Other prescribers in Great Neck, NY | 28 |
| Bromfenac Sodium | 23 |
| Timolol Maleate Other prescribers in Great Neck, NY | 19 |
| Eplerenone Other prescribers in Great Neck, NY | 18 |
| Dorzolamide Hcl Other prescribers in Great Neck, NY | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 9 companies reported 68 payments worth $54,780 in total to this clinician.
| Apellis Pharmaceuticals, Inc. | $28,370 |
|---|---|
| Alcon Vision LLC | $17,320 |
| Regeneron Healthcare Solutions, Inc. | $4,885 |
| Harrow Eye, LLC | $2,971 |
| Genentech USA, Inc. | $813 |
| Genentech, Inc. | $150 |
| Heidelberg Engineering, Inc. | $137 |
| Regeneron Pharmaceuticals, Inc. | $92.51 |
| Consulting Fee | $41,161 |
|---|---|
| Travel and Lodging | $10,899 |
| Food and Beverage | $2,720 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alcon Vision LLC Nov 20, 2025 | Consulting Fee UNITY; Constellation · Ophthalmology | $13,500 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Consulting Fee Syfovre · Ophthalmology | $11,403 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Seoul, Slovakia | $6,192 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $4,420 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Consulting Fee Syfovre · Ophthalmology | $3,801 |
| Harrow Eye, LLC Nov 7, 2025 | Consulting Fee TRIESENCE · OPTOMETRY | $2,800 |
| Alcon Vision LLC Feb 6, 2025 | Consulting Fee UNITY · Ophthalmology | $2,000 |
| Apellis Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee Syfovre · Ophthalmology | $1,629 |
| Apellis Pharmaceuticals, Inc. Sep 19, 2025 | Consulting Fee Syfovre · Ophthalmology | $1,358 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Fort Lauderdale, FL | $1,350 |
All 21 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Alcon Vision LLC Dec 4, 2025 | Travel and Lodging Constellation; UNITY · Ophthalmology · travel to Fort Worth, TX | $132 |
| Alcon Vision LLC Dec 4, 2025 | Travel and Lodging Constellation; UNITY · Ophthalmology · travel to Fort Worth, TX | $85.36 |
| Alcon Vision LLC Nov 20, 2025 | Consulting Fee UNITY; Constellation · Ophthalmology | $13,500 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging Constellation; UNITY · Ophthalmology · travel to Fort Worth, TX · in-kind | $493 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging NGENUITY; Constellation; Alcon Greishaber Finesse · Ophthalmology · travel to Fort Worth, TX · in-kind | $403 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging Constellation; NGENUITY; UNITY · Ophthalmology · travel to Fort Worth, TX · in-kind | $235 |
| Alcon Vision LLC Nov 14, 2025 | Travel and Lodging Constellation; NGENUITY; Finesse Sharkskin · Ophthalmology · travel to Fort Worth, TX · in-kind | $225 |
| Harrow Eye, LLC Nov 7, 2025 | Consulting Fee TRIESENCE · OPTOMETRY | $2,800 |
| Apellis Pharmaceuticals, Inc. Oct 24, 2025 | Consulting Fee Syfovre · Ophthalmology | $1,629 |
| Apellis Pharmaceuticals, Inc. Sep 19, 2025 | Consulting Fee Syfovre · Ophthalmology | $1,358 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Seoul, Slovakia | $6,192 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Seoul, Slovakia | $756 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Consulting Fee Syfovre · Ophthalmology | $250 |
| Apellis Pharmaceuticals, Inc. Aug 4, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Seoul, Slovakia | $219 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Consulting Fee Syfovre · Ophthalmology | $11,403 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Consulting Fee Syfovre · Ophthalmology | $3,801 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Fort Lauderdale, FL | $1,350 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Fort Lauderdale, FL | $627 |
| Apellis Pharmaceuticals, Inc. Jun 20, 2025 | Travel and Lodging Syfovre · Ophthalmology · travel to Fort Lauderdale, FL | $181 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee EYLEA HD · OPHTHALMOLOGY | $4,420 |
| Alcon Vision LLC Feb 6, 2025 | Consulting Fee UNITY · Ophthalmology | $2,000 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $1,598,024 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
Bayer HealthCare Pharmaceuticals Inc. - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD
Apellis Pharmaceuticals, Inc. - Port Delivery System of Ranibizumab Extension Study
Genentech, Inc. - OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY OF FARICIMAB in PATIENTS WITH nAMD
Genentech, Inc. - Study of the port delivery system with ranibizumab in patients with diabetic macular edema
Genentech, Inc. - Faricimab DME Long Term Extension Rhone X
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.